Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydroquinone + mometasone furoate + tretinoin
- Development stage
- Unknown
- Lead developer
- H&B Wellness
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Shynroz is a topical triple-combination cream containing hydroquinone, mometasone furoate, and tretinoin. It is developed by H&B Wellness and is indicated for the short-term, intermittent treatment of moderate-to-severe melasma and other hyperpigmentation disorders of the face. Hydroquinone acts as a skin-lightening agent by inhibiting tyrosinase, thereby reducing melanin synthesis. Tretinoin, a retinoid, promotes epidermal cell turnover and enhances the penetration of hydroquinone. Mometasone furoate, a medium-strength corticosteroid, reduces local inflammation, redness, and irritation associated with the other active ingredients. Together, these components work synergistically to fade dark spots and even out skin tone.
- Brand names
- Shynroz
- Other names
- hydroquinone + mometasone + tretinoinhydroquinone + mometasone furoate + tretinoin creamhydroquinone, mometasone furoate and tretinoin creammometasone furoate + hydroquinone + tretinoinmometasone furoate + hydroquinone + tretinoin creamtretinoin + hydroquinone + mometasone furoate
02
Targets
GR (Glucocorticoid receptor)TYR (Tyrosinase)RARA (Retinoic acid receptor alpha)RARB (Retinoic acid receptor beta)RARG (Retinoic acid receptor gamma)
Beyond the preview
Go deeper on hydroquinone + mometasone furoate + tretinoin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydroquinone + mometasone furoate + tretinoin.